Eli Lilly Shares Under Pressure Following Strategic Price Cuts

Investor sentiment toward Eli Lilly turned cautious last week, with the pharmaceutical giant’s stock declining approximately 4.5% over a five-day period. The move followed the company’s announcement of significant price reductions for its weight-loss medication, Zepbound, raising questions about the impact on future profitability in a key growth segment.

In early December, Eli Lilly unveiled new pricing for single-dose vials of Zepbound through its direct-to-consumer platform, LillyDirect. The adjustments represent a substantial decrease across all dosage strengths.

The company framed the decision as a move to improve patient access. Ilya Yuffa, Executive Vice President of Lilly USA, stated that significant cost and reimbursement barriers continue to Read more...